321 results on '"Bürger Katharina"'
Search Results
102. RELATIONSHIP BETWEEN LOCAL RESTING STATE ACTIVITY, β-AMYLOID DEPOSITION AND MEMORY PERFORMANCE IN THE DZNE: LONGITUDINAL COGNITIVE IMPAIRMENT AND DEMENTIA STUDY (DELCODE)
103. CORTICAL THINNING IN SUBJECTIVE COGNITIVE DECLINE WITH AND WITHOUT AD PATHOLOGY: DATA FROM THE DELCODE STUDY
104. OCCUPATIONAL COGNITIVE REQUIREMENTS ARE AN IMPORTANT PROXY MEASURE OF COGNITIVE RESERVE: EVIDENCE FROM THE AGECODE AND DELCODE STUDIES
105. CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large‐scale international multicenter study
106. Optical properties in relation to the carbonate layer and morphological studies of the brown alga Padina pavonica (L.) Thivy
107. OBJECT AND SCENE MEMORY ARE DIFFERENTIALLY ASSOCIATED WITH CSF MARKERS OF ALZHEIMER’S DISEASE AND MRI VOLUMETRY
108. LEFT FRONTAL HUB CONNECTIVITY PROBED DURING MEMORY TASK SUPPORTS RESERVE IN HEALTHY AGING
109. CONNECTIVITY OF THE LEFT FRONTAL CORTEX ATTENUATES DETRIMENTAL EFFECTS OF CSF-TAU ON MEMORY IN PRECLINICAL AND CLINICAL ALZHEIMER’S DISEASE
110. LOCAL AND GLOBAL RESTING STATE ALTERATIONS IN DIFFERENT STAGES DURING THE DEVELOPMENT OF ALZHEIMER’S DISEASE AS DEMONSTRATED IN THE DZNE DELCODE COHORT
111. MODELING OF HIDDEN CAUSES FOR DYNAMIC CHANGES IN STRUCTURAL INTEGRITY AND COGNITION IN SUBJECTIVE COGNITIVE DECLINE: A DELCODE PROJECT
112. CROSS-NETWORK COUPLING OF THE FRONTO-PARIETAL CONTROL NETWORK DURING MEMORY PERFORMANCE SUPPORTS PROTECTIVE EFFECTS OF EDUCATION IN AGING
113. WHAT IS MEMORABLE IS CONSERVED ACROSS HEALTHY AGING, EARLY ALZHEIMER’S DISEASE, AND NEURAL NETWORKS
114. PREVALENCE OF PRECLINICAL ALZHEIMER’S DISEASE IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE: COMPARISON OF THREE EUROPEAN MEMORY CLINIC SAMPLES
115. ASSOCIATION OF HIPPOCAMPAL RESTING STATE NETWORKS AND THE PRIMACY EFFECT AS A MARKER OF CONSOLIDATION IN AMNESTIC MCI
116. Lithium trial in Alzheimer's disease : a randomized, single-blind, placebo-controlled, multicenter 10-week study
117. The Determinants of Dementia after Stroke (DEDEMAS) Study: Protocol and Pilot Data
118. Characterization of the NIA‐AA Research Framework stage 2 in the longitudinal multicenter DELCODE study.
119. O1‐02‐01: Florbetaben for beta‐amyloid brain PET in Alzheimer's disease: Results of a multicenter phase 2 trial
120. Taste in mild cognitive impairment and Alzheimer’s disease
121. P2-025: Subcortical fiber tract integrity and the CERAD cognitive battery in patients with Alzheimer's disease: A multivariate approach to detect morphological correlates of cognitive failure
122. IC‐O1‐05: Twelve‐Month follow‐up study of Fractional Anisotropy changes in Mild Cognitive Impairment compared to healthy elderly subjects
123. IC-P-154: Subcortical fiber tract integrity and the CERAD cognitive battery in patients with Alzheimer's disease: A multivariate approach to detect morphological correlates of cognitive failure
124. P3-032: Elevated 3-Hydroxykynurenine serum levels in Alzheimer's disease
125. White Matter Microstructure in Relation to Education in Aging and Alzheimer's Disease1
126. Lithium Trial in Alzheimer's Disease
127. O3-02-03: Alteration of beta secretase (BACE1) functional candidate biomarkers in subjects with mild cognitive impairment and Alzheimer's disease
128. P3-069: Increased CSF-BACE1 activity is associated with APOE-ϵ4 genotype in subjects with mild cognitive impairment and Alzheimer's disease
129. P4-369: Lithium trial in Alzheimer's disease: A randomized, single-blinded, placebo-controlled, parallel group multicentre 10-week study
130. Increased CSF-BACE 1 activity is associated with ApoE-ε4 genotype in subjects with mild cognitive impairment and Alzheimer's disease
131. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease
132. International quality control survey of neurochemical dementia diagnostics
133. Decreased serum amyloid β1–42 autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1–42 peptide
134. Value of event‐related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's Disease
135. Polymorphisms in the α-2 macroglobulin gene in psychogeriatric patients
136. Serotonin transporter (5-HTT) gene polymorphism in psychogeriatric patients
137. Performance comparison of automated white matter lesion segmentation algorithms in the DELCODE Study: Neuroimaging / Optimal neuroimaging measures for early detection.
138. Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease ⁎ [⁎] This paper was presented in part by the 1st author at the 10th International Conference of Alzheimer’s Disease and Related ...
139. Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.
140. CSF and MRI biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer's disease
141. CSF markers as predictors for Alzheimer's disease in subjects with MCI: Effect of APOE genotype-adjusted cut offs
142. Florbetaben for beta-amyloid brain PET in Alzheimer's disease: Results of a multicenter phase 2 trial
143. Efficacy of [18F]BAY94-9172 Positron Emission Tomography in the Detection/Exclusion of Cerebral Amyloid Beta in Patients with Probable Alzheimer's Disease Compared with Healthy Volunteers: An Open-label, Global, Multicentre Study
144. Positive effects of a 6-month stage-specific cognitive intervention program on brain metabolism in subjects with amnestic mild cognitive impairment (aMCI) and mild Alzheimer's disease (AD)
145. Effects of a stage-specific cognitive intervention program in patients with mild cognitive impairment (MCI) and mild Alzheimer's disease (AD)
146. Subcortical fiber tract integrity and the CERAD cognitive battery in patients with Alzheimer's disease: A multivariate approach to detect morphological correlates of cognitive failure
147. Twelve-Month follow-up study of Fractional Anisotropy changes in Mild Cognitive Impairment compared to healthy elderly subjects
148. Blood-based microcirculation markers in Alzheimer's disease: Diagnostic value of CT-proET-1 in patients with amnestic mild cognitive impairment
149. Elevated 3-Hydroxykynurenine serum levels in Alzheimer's disease
150. Plasma Aß42/Aß40 ratio is decreased in amnestic Mild Cognitive Impairment (MCI) and mild Alzheimer's Disease (AD)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.